文献速递临床试验与 GCP

椎间孔处右侧C7神经切断术联合强化言语语言治疗与单纯强化言语语言治疗治疗慢性卒中后失语症:多中心随机对照试验

Right C7 neurotomy at the intervertebral foramen plus intensive speech and language therapy versus intensive speech and language therapy alone for chronic post-stroke aphasia: multicentre, randomised controlled trial.
PubMed 文献 · BMJ · 2025-06-25

这项多中心、评估者盲法随机对照试验纳入50例卒中后慢性失语症患者,比较椎间孔处右侧C7神经切断术联合三周强化言语语言治疗与单纯三周强化言语语言治疗。联合组在波士顿命名测试评分改善上优于对照组,且疗效维持至六个月,未报告治疗相关严重不良事件。

要点

  • 联合组波士顿命名测试评分平均增加11.16分,对照组增加2.72分,组间差异8.51分(95%CI 5.31至11.71,P<0.001)。
  • 六个月时组间波士顿命名测试评分差异仍稳定,为8.26分(95%CI 4.16至12.35,P<0.001)。
  • 联合组失语商改善亦显著优于对照组,一个月时差异7.06分(95%CI 4.41至9.72,P<0.001),未报告治疗相关严重不良事件。

核心结论

  • 椎间孔处右侧C7神经切断术联合三周强化言语语言治疗,与单纯三周强化言语语言治疗相比,在六个月期间与语言功能更大改善相关。
  • 未报告严重不良事件或长期困扰症状或功能丧失。

研究设计与样本

  • 多中心、评估者盲法随机对照试验,在中国大陆四个中心开展。
  • 纳入50例年龄40至65岁、单次左半球卒中后失语超过一年的成人,按1:1随机分组并按治疗中心分层,每组25例。
  • 干预为椎间孔处右侧C7神经切断术联合三周强化言语语言治疗,对照为延迟一周后三周强化言语语言治疗。
  • 主要结局为60项波士顿命名测试(BNT,评分0至60分,分数越高命名功能越好)从基线至干预后一周的变化。

主要发现

  • 一个月时BNT评分平均增加:神经切断联合言语语言治疗组11.16分,对照组2.72分,差异8.51分(95%CI 5.31至11.71,P<0.001)。
  • 六个月时BNT评分组间差异为8.26分(95%CI 4.16至12.35,P<0.001)。
  • 一个月时失语商组间差异为7.06分(95%CI 4.41至9.72,P<0.001),联合组优于对照组。
  • 患者报告卒中后日常生活活动能力和抑郁亦改善。
  • 未报告治疗相关严重不良事件。

关键数值与推荐

  • 主要结局为60项波士顿命名测试评分变化,评分范围0至60分。
  • 次要结局包括采用西部失语症成套测验计算的失语商评估的失语严重程度变化,以及患者报告的生活质量和卒中后抑郁结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether right neurotomy of the seventh cervical nerve (C7) at the intervertebral foramen plus intensive speech and language therapy (SLT) improves language function compared intensive SLT alone in patients with chronic aphasia after stroke. DESIGN: Multicentre, assessor blinded, randomised controlled trial. SETTING: Four centres in mainland China. PARTICIPANTS: 50 adults aged 40-65 years with aphasia for more than one year after a single left hemispheric stroke. INTERVENTIONS: Participants were randomised 1:1 to receive either C7 neurotomy plus three weeks of intensive SLT or three weeks of intensive SLT only, stratified by treatment centre. MAIN OUTCOME MEASURES: The primary outcome was change in score on the 60 item Boston naming test (BNT, scores 0-60, with higher scores indicating better naming function) from baseline to one week after C7 neurotomy plus intensive SLT for three weeks or intensive SLT for three weeks after deferral for one week (control group). Secondary outcomes included change in severity of aphasia using the aphasia quotient, calculated using the western aphasia battery, and patient reported outcomes on quality of life and depression after stroke. RESULTS: From 25 July 2022 to 31 July 2023, 322 out of 1086 patients received a diagnosis of post-stroke aphasia and were screened for eligibility. 50 eligible participants were randomly assigned to treatment groups (25 in each). Mean increase in BNT score was 11.16 points in the neurotomy plus SLT group and 2.72 points in the control group at one month (difference 8.51 points, 95% confidence interval (CI) 5.31 to 11.71, P<0.001). The between group difference in BNT score remained stable at six months (difference 8.26 points, 4.16 to 12.35, P<0.001). In addition, the aphasia quotient improved significantly in the neurotomy plus SLT group versus control group (difference at one month 7.06 points, 4.41 to 9.72, P<0.001), as did patient reported activities of daily living and post-stroke depression. No treatment related severe adverse events were reported. CONCLUSIONS: C7 neurotomy plus three weeks of intensive SLT was associated with a greater improvement in language function compared with three weeks of intensive SLT alone over a period of six months. No severe adverse events or long term troublesome symptoms or functional loss were reported. TRIAL REGISTRATION: Chinese Clinical Trial Register ChiCTR2200057180.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Feng J, Hu R, Lyu M, et al. Right C7 neurotomy at the intervertebral foramen plus intensive speech and language therapy versus intensive speech and language therapy alone for chronic post-stroke aphasia: multicentre, randomised controlled trial. BMJ. 2025. PMID: 40562426. doi:10.1136/bmj-2024-083605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。